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AT WHAT COST? A REVIEW OF DRUG 
ACQUISITION COST ISSUES IN MODELLED 
ECONOMIC EVALUATIONS.
Wonder M1, Backhouse M2, Gnanasakthy A2
1Novartis Pharmaceuticals, Sydney, Australia; 2Novartis
Pharmaceuticals, Basel, Switzerland
OBJECTIVE: Payers are increasingly using economic evaluation
methods in their decision-making process for new health tech-
nologies. Payers often only have the results from short-term clin-
ical trials at their decision time point. For new drugs for chronic
diseases/conditions such as hypertension, diabetes mellitus &
multiple sclerosis, they may want to see how these beneﬁts trans-
late into long term outcomes via a model (i.e. a modelled 
economic evaluation). The appropriate time horizon for some
modelled evaluations may be greater than the drug’s remaining
patent life. In a situation where the acquisition cost of a new
drug is the major cost driver, the use of an adjusted acquisition
cost after patent expiry could have a major effect on the mod-
elled cost-effectiveness ratio. We set out to review issues associ-
ated with the acquisition costs of (new) drugs in modelled
economic evaluations. METHODS: We reviewed the latest pub-
lished versions of the guidelines of the major drug reimburse-
ment agencies (PBAC, NICE, DQTC, AMCP) and health
economics reference text books (Gold, Drummond, Bootman) as
well as modelled economic evaluations of drugs published in
ISPOR Value in Health in 2003 & 2004 to see how others have
dealt with this issue. RESULTS: Although we could ﬁnd frequent
citations on the discounting of the acquisition cost of drugs if
the time horizon of an evaluation is greater than 12 months, we
found very little discussion on the merits of the adjustment of
drug acquisition costs post patent expiry. CONCLUSION: The
concept of adjusting the acquisition costs of (new) drugs after
their patent expiry in modelled economic evaluations is under-
developed. The merits & demerits of the concept will be dis-
cussed in more detail in the poster.
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USING MARKOV MATRICES TO INTEGRATE RISK/BENEFIT
CONSIDERATIONS OF HEALTH CARE INTERVENTIONS
EVALUATED USING HEALTH-RELATED QUALITY OF 
LIFE INSTRUMENTS
Casado A, Herdman MJ
3D Health Research, Barcelona, Barcelona, Spain
OBJECTIVES: To show how Markov matrices can be used to
quantify and integrate the risks and beneﬁts of health care inter-
ventions when these are measured using health-related quality of
life (HRQOL) instruments. To provide an example of this type
of evaluation for an HRQOL measure which uses Likert scales
for the response options. METHODS: A brief theoretical expla-
nation of the nature and purposes of Markov matrices will be
followed by practical examples of their potential in the ﬁeld of
outcomes research using the COOP-WONCA charts in a hypo-
thetical longitudinal study. RESULTS: Markov matrices deﬁning
between-state transition probabilities (HRQOL dimension score
at each measurement time point) are developed and use of the
matrices will be illustrated by providing quantitative deﬁnitions
and interpretations of the probabilities associated with the prin-
cipal sub-matrices (main diagonal, upper and lower triangles,
upper and lower linear bounds, and simple elements). CON-
CLUSIONS: The use of theoretical deﬁnitions and practical
examples will be useful in introducing and discussing the appli-
cation of Markov matrices as a means of integrating risk and
beneﬁt considerations associated with health care interventions
measured using HRQOL instruments.
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BRIDGING BEYOND REGRESSION–ARTIFICIAL NEURAL
NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY
Yu AP1,Yu YF2, Nichol MB3
1University of Southern California, Los Angeles, CA, USA;
2HealthCore, Inc, Wilmington, DE, USA; 3University of Southern
California, School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: Linear regression was often used to develop
models bridging SF-36 to utility, with assumptions of linearity
and independence among subscales. Artiﬁcial neural networks
(ANN) are capable to detect complex patterns among data, thus
may provide as a promising alternative algorithm to bridge 
from SF-36 subscales to utility. This study is to investigate the
predictive power of an ANN algorithm, in contrast to that of
linear regression. METHODS: Data included a cohort of 6923
Southern California Kaiser Permanente members who ﬁlled both
SF-36 and HUI2 during 1994–1995. A random sample contain-
ing half of total members was used as a training sample to gen-
erate mapping algorithms based on linear models and ANN
respectively, and the other half was used as testing sample to
compare accuracy of prediction between the two methods. Both
models used 8 domain scores plus age and gender as predictors.
Model prediction accuracy was evaluated based on mean
squared error, mean absolute error, percentage of correct pre-
diction within 0.01, 0.03 and 0.1 error range. Observed and 
predicted utility scores by both methods in testing sample were
summarized and compared. This random sample tests were 
conducted multiple times in order to examine the stability of
such cross-validation procedure. RESULTS: The “trained”
neural network model was a 10-3-1 network. After cross-
validation, the mean squared error was 0.128 for linear model
vs. 0.127 for ANN, and absolute error was 0.095 vs. 0.093.
Within 0.01 error range, linear model predicted 8.58% correctly,
and ANN 8.73%. The rates were 23.8% vs. 24.9% with 0.03
error range, and 63.4% vs. 65.4% with 0.10 error range. The
testing process was repeated multiple times and results were
stable. CONCLUSIONS: When testing to an independent
sample, the bridging algorithm based on ANN showed improved




HEALTH CARE AND WORKLOSS COSTS OF OPIOID ABUSE
AMONG AN EMPLOYED POPULATION IN THE US
White AG1, Birnbaum H1, Mareva MN1, Daher M1, Katz N2,
Vallow S3, Schein J3, Doshi D4, Sikirica V3
1Analysis Group, Inc, Boston, MA, USA; 2Inﬂexxion, Inc, Newton, MA,
USA; 3Janssen Medical Affairs, LLC,Titusville, NJ, USA; 4Janssen
Medical Affairs, LLC, San Diego, CA, USA
OBJECTIVES: To describe demographics of opioid abusers, and
compare medical/drug utilization, workloss patterns, and
medical costs of opioid abusers to those of a control group,
1999–2002. METHODS: A claims database of insured patients
was used to identify patients with claims with ICD-9 codes for
opioid abuse (304.0, 304.7, 305.5, and 965.0). In total, 740 such
patients aged 12–64 were identiﬁed. A control group of non-
abusers was selected using a matched sample (by age, gender, and
census region). All costs were calculated from a private payer’s
perspective in 2003 USD. RESULTS: Opioid abusers, compared
to controls, had higher medical and drug utilization. Almost
60% of opioid abusers had claims for opioids, versus 20% for
controls. Prevalence rates for hospital inpatient care for opioid
abusers were 12 times higher than controls (p < 0.01). Opioid
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abusers were 1.5-fold as likely to have medically related absen-
teeism days, and 8.5 times as likely to have a disability claim
compared to controls (p < 0.01). Opioid abusers had higher
average annual medically related absenteeism days compared to
controls (26.4 days vs. 5.7 days, p < 0.01). Mean annual direct
health care costs for opioid abusers were over eight times higher
than controls ($15,884 vs. $1830, p < 0.01). Hospital inpatient
and doctor/outpatient costs accounted for 46% ($7239) and
31% ($5000) of opioid abusers’ health care costs, versus 17%
($310) and 50% ($906), respectively, for controls. Mean annual
indirect workloss costs for opioid abusers were over eight times
higher than controls ($4167 vs. $502, p < 0.01). CONCLU-
SIONS: These high costs were driven partly by high utilization
rates of medical services and prescription drugs, and higher
prevalence of workloss. Our estimates may be conservative as
only patients diagnosed with abuse were included. To the extent
that the abuse is prescription opioid abuse, payers should ensure
appropriate access to opioids while considering abuse liability of
drugs on formulary.
(For abstract PMH2 see page 256) MH2
EMERGENCY DEPARTMENT USE FOR ACUTE ALCOHOL
INTOXICATION BY COLLEGE AGE PERSONS: TIME AND COST
OF TREATMENT
O’Brien JA1, Pitoniak-Morse C1, Jacobs LM2
1Caro Research Institute, Concord, MA, USA; 2University of
Connecticut Medical School, Farmington, CT, USA
OBJECTIVES: To examine use, timing and cost of Emergency
Department (ED) visits by those of college age (17–22 years) for
acute alcohol intoxication. METHODS: Cases were identiﬁed
from Massachusetts 2002 ED and hospital databases using ICD-
9 principal diagnosis codes 305.00–305.09. Hospital cases were
limited to those admitted via ED. Cost estimates include facility,
accommodations and ancillary services, reported in 2002 USD.
Charges were adjusted using a 0.55 cost-to-charge ratio.
RESULTS: Of 1803 cases identiﬁed, 52% were male and 55%
were less than 20-years old. Ambulances were used to transport
54%; law enforcement was involved in 1.5% of cases. The
majority (69%) arrived between 10:00 PM and 4:00 AM, and
70% of all visits occurred Friday through Sunday. Signiﬁcantly
(p = 0.004) more visits occurred in September and October than
any other month. The majority (94%) were treated and released
from ED, 1% was hospitalized, 2% eloped or left AMA, 2%
were transferred and 1% was recorded as unknown. Mean dura-
tion of ED visit was 5.4 hours (median: 4). Mean cost per ED
visit was $482 (median: $382) for those treated and released,
and $537 (median: $460) for those hospitalized. On average,
those admitted (n = 20) spent 2.5 days (median: 1) in the hos-
pital at a cost of $4540 (median: $2154). The cumulative hours
of ED time used in one year for treating alcohol intoxication in
this age group was 8254. Cumulative cost of ED and inpatient
care for the year was roughly $938,000. Managed care organi-
zations and commercial insurers were the responsible payers for
most cases (60%). Self-pay was noted for 24%. CONCLU-
SIONS: Acute alcohol intoxication among those of college age
results in a substantial direct medical cost, as well as an oppor-
tunity cost for ED resources during the year, particularly at the
start of the school year.
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QUALITY-ADJUSTED LIFE YEARS GAINED WITH
BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION
Campbell HM1, Raisch DW1, Ling W2
1VA Cooperative Studies Program, Albuquerque, NM, USA; 2David
Geffen School of Medicine at UCLA, Los Angeles, CA, USA
OBJECTIVES: To determine quality-adjusted life-year (QALY)
gains associated with buprenorphine treatment for opiate addic-
tion, and estimate the potential cost savings of this treatment
from the societal perspective. METHODS: In a randomized 
clinical trial of buprenorphine therapy, subjects completed the
short-form-36 (SF-36) at baseline and every four weeks through
week-16, creating up to ﬁve data collection points for each
patient. We converted SF-36 data to SF-6D to calculate QALYs
for each patient-month through published techniques based
upon standard gamble methods. Dependent t-tests were used to
identify signiﬁcant differences in QALYs at baseline versus
QALYs at the end of each month. Our base case used a buprenor-
phine 12mg/day dosage plus annual buprenorphine treatment
clinic costs ($2356/person). We incorporated social costs of
untreated opiate addiction from the literature ($42,957/person-
year) and performed a sensitivity analysis using 8mg and 16mg
buprenorphine dosages. RESULTS: Due to dropouts, our sample
size was 100, 80, 69, 59, and 44 patients at baseline and months
one-four, respectively. QALY values (mean ± SD) for each month
were: 0.734 ± 0.091 at baseline, 0.761 ± 0.068 at month-one,
0.751 ± 0.087 at month-two, 0.754 ± 0.087 at month-three, and
0.757 ± 0.090 at month-four. Thus, an improvement of 0.027
QALYs (P = 0.008) between baseline and month-one occurred
(95% CI = 0.007–0.047). There were no other signiﬁcant
improvements, possibly due to patient dropouts. The sensitivity
analysis showed direct medical costs for buprenorphine treat-
ment ranged from $4206 to $6056 per person-year. By incorpo-
rating societal costs of untreated opiate addiction, a savings of
$36,901 to $38,752 per person-year was estimated. CONCLU-
SIONS: From a societal perspective, buprenorphine treatment
saves money and increases QALYs. For every 37 (95%CI =
21–143) patients treated there is a gain of one QALY. Wide-
spread adoption of proper ofﬁce-based buprenorphine treatment
is clearly indicated; undertreatment leads to exorbitant social
costs without QALY gains.
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COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY
DISORDERS
García-Contreras F, Castro-Ríos A, Nevarez-Sida A,
Constantino-Casas P, Contreras-Hernández I, Mould J,
Garduño-Espinosa J
Mexican Institute of Social Security, Mexico City, Mexico
OBJECTIVE: To estimate cost-effectiveness of Alprazolam
versus Clonazepam, Fluoxetine and Imipramine in anxiety dis-
orders in the Mexican Institute of Social Security (IMSS).
METHODS: A cost-effectiveness study was carried out with a
time horizon of one year, no discount rate was used. Utilization
of resources and effectiveness data were taken from an expert
panel of psychiatrists working at the IMSS and private sector.
Inclusion criteria for experts were: psychiatrists with more than
ﬁve years of clinical experience, that were certiﬁed by the
Mexican Council of Psychiatry and that had experience in using
the studied drugs in anxiety disorders. Use of resources included
hospitalisation, emergency services, visits, laboratory and diag-
nostic tests, as well as pocket expenses. Unit costs were taken
from Administrative and Financial departments of IMSS. Costs
were expressed in 2004 USD. Effectiveness measure was days
free of symptoms. Sensitivity analysis was univariate and prob-
abilistic. RESULTS: Annual treatment cost of anxiety disorders
with Alprazolam was $13,110, with Clonazepam $13,367, with
Fluoxetine $13,423 and with Imipramine $14,803. Effectiveness
results were 224 days without symptoms for Alprazolam, 232
